Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TERT | O14746 | 14/20 | 0.40 |
| ▸ | HTR7 | P34969 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 2/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.36 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.36 |
| ▸ | ATM | Q13315 | 1/20 | 0.36 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.33 |
| ▸ | CCR1 | P32246 | 1/20 | 0.32 |
| ▸ | HSD17B1 | P14061 | 1/20 | 0.32 |
| ▸ | HSD17B2 | P37059 | 1/20 | 0.32 |
| ▸ | HSD17B14 | Q9BPX1 | 1/20 | 0.32 |
| ▸ | NPC1 | O15118 | 1/20 | 0.32 |
| ▸ | USP2 | O75604 | 1/20 | 0.32 |
| ▸ | POLB | P06746 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30570368 | 0.87 | TERT (0.41) | TERTHTR7MEN1KMT2ACCR1 | |
| SCHEMBL25391492 | 0.87 | TERT (0.41) | TERTHTR7MEN1KMT2ACCR1 | |
| SCHEMBL3340077 | 0.84 | HTR7 (0.41) | TERTHTR7CCR1 | |
| SCHEMBL2024281 | 0.75 | CA12 (0.36) | TERTHSP90AA1 | |
| SCHEMBL2151538 | 0.74 | CCR1 (0.48) | TERTMEN1KMT2AHSP90AA1CCR1 | |
| SCHEMBL29476108 | 0.74 | CCR1 (0.48) | TERTMEN1KMT2AHSP90AA1CCR1 | |
| SCHEMBL805864 | 0.73 | MAPT (0.64) | MEN1KMT2AATMCCR1HSD17B1 | |
| SCHEMBL12640990 | 0.72 | HTR7 (0.40) | HTR7MEN1KMT2AHSP90AA1ATM | |
| SCHEMBL5981646 | 0.72 | NPC1 (0.44) | TERTHTR7MEN1KMT2AHSD17B1 | |
| SCHEMBL12578264 | 0.72 | ALDH1A1 (0.50) | MEN1KMT2ANPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7968552-B2 | Oxadiazolidinedione compound | ASTELLAS PHARMA INC. (JP) | 2011-06-28 | — | — | US | disclosed |
| US-20090186909-A1 | Oxadiazolidinedione Compound | ASTELLAS PHARMA INC. (JP) | 2009-07-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090186909-A1 | Oxadiazolidinedione Compound | GPR119, GPR39, GPR65 | TERT 4046/4885HTR7 976/4885MEN1 3315/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.